In:
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, Wiley, Vol. 12, No. 5 ( 2014-05), p. 401-407
Abstract:
TNF‐α inhibitors have been associated with induction of autoantibodies and autoimmune diseases. We retrospectively evaluated the incidence of autoantibodies ANA, ENA, anti‐dsDNA, the occurrence of clinical symptoms and possibly related treatment failure. Patients and methods The titers of ANA, ENA and anti‐dsDNA were evaluated from blood samples every six months in 128 patients receiving a TNF‐α inhibitor (adalimumab,
etanercept, infliximab). Results Overall 37 % of 128 patients treated with anti‐TNF‐α drug developed autoantibodies, mostly induced by infliximab; 48.48 % of patients who received infliximab presented autoantibodies. One patient developed a drug‐induced lupus erythematosus.
Forty‐five patients were switched to one or more additional TNF‐α inhibitors and 25 developed autoantibodies. Conclusions An increased autoantibody titer is not predictive of treatment failure; particular attention to all phenomena suggestive for autoimmunity is needed in patients with a positive autoantibody titer. Further studies are needed to clarify the role of autoantibodies during anti‐TNF‐α therapy.
Type of Medium:
Online Resource
ISSN:
1610-0379
,
1610-0387
DOI:
10.1111/ddg.2014.12.issue-5
DOI:
10.1111/ddg.12339_suppl
Language:
English
Publisher:
Wiley
Publication Date:
2014
detail.hit.zdb_id:
2099463-1
Permalink
